Cargando…

Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study

BACKGROUND: Psychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed. METHODS: Eighty PD patients with psy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ecker, Daniel, Unrath, Alexander, Kassubek, Jan, Sabolek, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704166/
https://www.ncbi.nlm.nih.gov/pubmed/19515253
http://dx.doi.org/10.1186/1471-2377-9-23
_version_ 1782168906607099904
author Ecker, Daniel
Unrath, Alexander
Kassubek, Jan
Sabolek, Michael
author_facet Ecker, Daniel
Unrath, Alexander
Kassubek, Jan
Sabolek, Michael
author_sort Ecker, Daniel
collection PubMed
description BACKGROUND: Psychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed. METHODS: Eighty PD patients with psychotic episodes were compared to an age-matched control group of PD patients without psychotic episodes (n = 120) in a cross-sectional retrospective study. RESULTS: We found a positive correlation between psychotic episodes and dementia, number of concomitant medication, and pergolide intake. Odds ratio calculation confirmed the association with dementia. With respect to dopaminergic treatment, pergolide showed the highest odds ratio, levodopa the lowest. An adjusted logistic regression model confirmed the strong association with psychotic episodes and pergolide and no association with levodopa (adjusted odds ratio 2.01 and 0.11, respectively). CONCLUSION: The analysis indicates that dementia and concomitant medication are factors in PD associated with psychotic symptoms. Furthermore, different dopaminergic drugs showed markedly different associations with psychotic symptoms
format Text
id pubmed-2704166
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27041662009-07-01 Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study Ecker, Daniel Unrath, Alexander Kassubek, Jan Sabolek, Michael BMC Neurol Research Article BACKGROUND: Psychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed. METHODS: Eighty PD patients with psychotic episodes were compared to an age-matched control group of PD patients without psychotic episodes (n = 120) in a cross-sectional retrospective study. RESULTS: We found a positive correlation between psychotic episodes and dementia, number of concomitant medication, and pergolide intake. Odds ratio calculation confirmed the association with dementia. With respect to dopaminergic treatment, pergolide showed the highest odds ratio, levodopa the lowest. An adjusted logistic regression model confirmed the strong association with psychotic episodes and pergolide and no association with levodopa (adjusted odds ratio 2.01 and 0.11, respectively). CONCLUSION: The analysis indicates that dementia and concomitant medication are factors in PD associated with psychotic symptoms. Furthermore, different dopaminergic drugs showed markedly different associations with psychotic symptoms BioMed Central 2009-06-10 /pmc/articles/PMC2704166/ /pubmed/19515253 http://dx.doi.org/10.1186/1471-2377-9-23 Text en Copyright © 2009 Ecker et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ecker, Daniel
Unrath, Alexander
Kassubek, Jan
Sabolek, Michael
Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
title Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
title_full Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
title_fullStr Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
title_full_unstemmed Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
title_short Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
title_sort dopamine agonists and their risk to induce psychotic episodes in parkinson's disease: a case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704166/
https://www.ncbi.nlm.nih.gov/pubmed/19515253
http://dx.doi.org/10.1186/1471-2377-9-23
work_keys_str_mv AT eckerdaniel dopamineagonistsandtheirrisktoinducepsychoticepisodesinparkinsonsdiseaseacasecontrolstudy
AT unrathalexander dopamineagonistsandtheirrisktoinducepsychoticepisodesinparkinsonsdiseaseacasecontrolstudy
AT kassubekjan dopamineagonistsandtheirrisktoinducepsychoticepisodesinparkinsonsdiseaseacasecontrolstudy
AT sabolekmichael dopamineagonistsandtheirrisktoinducepsychoticepisodesinparkinsonsdiseaseacasecontrolstudy